We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ventas Stock Rallies 23.6% in Six Months: Will the Trend Continue?
Read MoreHide Full Article
Key Takeaways
Ventas shares jumped 23.6% in six months, outperforming the industry's 3.1% growth.
VTR benefits from senior housing demand, with the 80 plus population set to rise 28% in five years.
VTR expands portfolio and liquidity, with $5.3B available and a strong SHOP NOI growth outlook.
Shares of Ventas (VTR - Free Report) have risen 23.6% over the past six months compared with the industry’s 3.1% growth.
Its diverse portfolio of healthcare real estate assets in the key markets of the United States and the U.K. is set to capitalize on the favorable industry fundamentals. The senior housing operating portfolio (SHOP) is likely to benefit from the aging population and the rising healthcare expenditures by senior citizens. The outpatient medical portfolio is expected to gain from the favorable outpatient visit trends. Ventas’ accretive investments to expand its research portfolio also look promising.
Analysts seem positive on this Zacks Rank #2 (Buy) REIT. The Zacks Consensus Estimate for its 2026 FFO per share has been revised marginally northward to $3.84 over the past month.
Image Source: Zacks Investment Research
Factors Behind VTR’s Stock Price Rise
Ventas is still in the early innings of the multiyear growth opportunity in senior housing, as the 80+ aged population is surging, and the U.S. senior housing construction starts have fallen to historic lows. Per the company’s fourth-quarter 2025 earnings presentation, the U.S. population aged 80 years and above is expected to grow 28% in the next five years, driving significant demand for senior housing. Hence, the company is well-prepared to capitalize on this opportunity.
Ventas’ senior housing portfolio is positioned in markets with favorable demographics, strong net absorption and affordability. This healthcare REIT is experiencing healthy occupancy levels, backed by an acceleration in SHOP demand. In 2026, Ventas expects its SHOP segment's same-store cash NOI to grow between 13% and 17%.
Ventas is carrying out accretive investments to enhance its research portfolio, which is essential for the delivery of crucial healthcare services and research related to life-saving vaccines and therapeutics. Outpatient medical and research assets are aligned with institutional demand, with several top-tier research universities and credit tenancy. With top-rated tenants and long-lease terms, its high-quality portfolio assures steady growth in cash flows. Ventas expects the OM&R portfolio's same-store cash NOI to grow in the range of 2-3% in 2026.
Ventas follows a disciplined capital-recycling strategy through which it disposes of non-core assets and redeploys the proceeds in premium asset acquisitions. Such efforts help the company improve its financial position and address the concerns surrounding the tenant base. In 2025, Ventas sold three senior housing communities in its SHOP segment, six properties in its OM&R segment and 14 properties in its NNN segment for aggregate consideration of $223.2 million. In 2025, Ventas acquired 52 senior housing communities reported within its SHOP segment for an aggregate purchase price of $2.3 billion.
Ventas maintains a healthy balance sheet. It has been making efforts to enhance its liquidity position and financial strength. As of Dec. 31, 2025, the company had approximately $5.3 billion of liquidity, which includes availability under its unsecured revolving credit facility, cash and cash equivalents and unsettled equity forward sales agreements outstanding. In the fourth quarter of 2025, its net debt to further adjusted EBITDA improved to 5.2X from 6.0X at the prior-year quarter end. The company expects its leverage to continue to trend lower in 2026.
Risks Likely to Affect VTR’s Positive Trend
Ventas operates in a competitive market and competes with national and local healthcare operators. The company’s operators contend with peers for occupancy. This significantly limits its power to raise rents and drive profitability, as well as crack deals at attractive rates.
The company has a substantial debt burden, and its total debt as of Dec. 31, 2025 was approximately $12.65 billion. With a high level of debt, interest expenses are likely to remain elevated.
The Zacks Consensus Estimate for CLDT’s 2026 FFO per share is pegged at $1.20, which indicates year-over-year growth of 17.7%.
The consensus estimate for TRNO’s full-year FFO per share is pinned at $2.79, which calls for a marginal increase from the year-ago period.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO) — a widely used metric to gauge the performance of REITs.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Shutterstock
Ventas Stock Rallies 23.6% in Six Months: Will the Trend Continue?
Key Takeaways
Shares of Ventas (VTR - Free Report) have risen 23.6% over the past six months compared with the industry’s 3.1% growth.
Its diverse portfolio of healthcare real estate assets in the key markets of the United States and the U.K. is set to capitalize on the favorable industry fundamentals. The senior housing operating portfolio (SHOP) is likely to benefit from the aging population and the rising healthcare expenditures by senior citizens. The outpatient medical portfolio is expected to gain from the favorable outpatient visit trends. Ventas’ accretive investments to expand its research portfolio also look promising.
Analysts seem positive on this Zacks Rank #2 (Buy) REIT. The Zacks Consensus Estimate for its 2026 FFO per share has been revised marginally northward to $3.84 over the past month.
Image Source: Zacks Investment Research
Factors Behind VTR’s Stock Price Rise
Ventas is still in the early innings of the multiyear growth opportunity in senior housing, as the 80+ aged population is surging, and the U.S. senior housing construction starts have fallen to historic lows. Per the company’s fourth-quarter 2025 earnings presentation, the U.S. population aged 80 years and above is expected to grow 28% in the next five years, driving significant demand for senior housing. Hence, the company is well-prepared to capitalize on this opportunity.
Ventas’ senior housing portfolio is positioned in markets with favorable demographics, strong net absorption and affordability. This healthcare REIT is experiencing healthy occupancy levels, backed by an acceleration in SHOP demand. In 2026, Ventas expects its SHOP segment's same-store cash NOI to grow between 13% and 17%.
Ventas is carrying out accretive investments to enhance its research portfolio, which is essential for the delivery of crucial healthcare services and research related to life-saving vaccines and therapeutics. Outpatient medical and research assets are aligned with institutional demand, with several top-tier research universities and credit tenancy. With top-rated tenants and long-lease terms, its high-quality portfolio assures steady growth in cash flows. Ventas expects the OM&R portfolio's same-store cash NOI to grow in the range of 2-3% in 2026.
Ventas follows a disciplined capital-recycling strategy through which it disposes of non-core assets and redeploys the proceeds in premium asset acquisitions. Such efforts help the company improve its financial position and address the concerns surrounding the tenant base. In 2025, Ventas sold three senior housing communities in its SHOP segment, six properties in its OM&R segment and 14 properties in its NNN segment for aggregate consideration of $223.2 million. In 2025, Ventas acquired 52 senior housing communities reported within its SHOP segment for an aggregate purchase price of $2.3 billion.
Ventas maintains a healthy balance sheet. It has been making efforts to enhance its liquidity position and financial strength. As of Dec. 31, 2025, the company had approximately $5.3 billion of liquidity, which includes availability under its unsecured revolving credit facility, cash and cash equivalents and unsettled equity forward sales agreements outstanding. In the fourth quarter of 2025, its net debt to further adjusted EBITDA improved to 5.2X from 6.0X at the prior-year quarter end. The company expects its leverage to continue to trend lower in 2026.
Risks Likely to Affect VTR’s Positive Trend
Ventas operates in a competitive market and competes with national and local healthcare operators. The company’s operators contend with peers for occupancy. This significantly limits its power to raise rents and drive profitability, as well as crack deals at attractive rates.
The company has a substantial debt burden, and its total debt as of Dec. 31, 2025 was approximately $12.65 billion. With a high level of debt, interest expenses are likely to remain elevated.
Other Stocks to Consider
Some other top-ranked stocks from the broader REIT sector are Chatham Lodging Trust REIT (CLDT - Free Report) , sporting a Zacks Rank #1 (Strong Buy), and Terreno Realty (TRNO - Free Report) , carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for CLDT’s 2026 FFO per share is pegged at $1.20, which indicates year-over-year growth of 17.7%.
The consensus estimate for TRNO’s full-year FFO per share is pinned at $2.79, which calls for a marginal increase from the year-ago period.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO) — a widely used metric to gauge the performance of REITs.